Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Beta-blocking agents are established treatments for mild-to-moderate heart failure.
• Efficacy of beta-blockers in severe heart failure remains less understood.

Purpose of the Study:

• To evaluate the efficacy of carvedilol in patients with severe heart failure.

Main Methods:

• A randomized, double-blind trial involving 2289 patients with severe heart failure (ejection fraction <25%).
• Patients received either placebo or carvedilol for an average of 10.4 months.

Main Results:

• Carvedilol reduced the combined risk of death or cardiovascular hospitalization by 27% (P=0.00002).
• Carvedilol decreased the combined risk of death or heart failure hospitalization by 31% (P=0.000004).
• Carvedilol treatment led to fewer hospital days and a lower incidence of serious adverse events.

Conclusions:

• Carvedilol addition to conventional therapy improves outcomes in severe heart failure.
• It reduces clinical deterioration, hospitalizations, and serious adverse events in euvolemic patients.